Business
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
MIAMI, April 30, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2026.
About this update from Summit Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":311,"url":"https://media.zenfs.com/en/business-wire.com/3ad04e88997758a30b8821c36eafec6a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ljen_e04jS11ZpaR9Ia5Cg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYyMg--/https://media.zenfs.com/en/business-wire.com/3ad04e88997758a30b8821c36eafec6a","width":480,"height":311}},"lazy":false},{"type":"text","content":"Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"Update Conference Call to be Held on June 1, 2026 after ASCO Plenary Session","length":76,"tagName":"p","attribs":{}},{"type":"text","content":"HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Final PFS Data Expected in Second Half of 2026 with Interim OS Analyses Planned","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"HARMONi-3 Non-Squamous Cohort of Global Phase III 1L NSCLC Study: PFS Data Expected in the First Half 2027","length":106,"tagName":"p","attribs":{}},{"type":"text","content":"MIAMI, April 30, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2026.","length":284,"tagName":"p"},{"type":"text","content":"Clinical & Operational Updates","length":34,"tagName":"p"},{"type":"text","content":"Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule:","length":275,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Since in-licensing ivonescimab, from Akeso Inc. (Akeso, HKEX Code: 9926.HK) in January 2023, over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 70,000 patients have been treated in the commercial setting with ivonescimab in China, as noted and updated by Akeso. Summit has rights to d...